RY 133.21 -0.0675% TD 78.64 0.4599% SHOP 95.75 0.136% CNR 174.55 -0.2172% ENB 46.51 1.3511% CP 115.18 -0.3375% BMO 125.12 -0.1197% TRI 207.83 -1.3153% CNQ 105.4 -0.8467% BN 52.885 -1.5544% ATD 75.13 -0.186% CSU 3670.4399 -1.1052% BNS 64.03 -0.2959% CM 64.91 0.1698% SU 52.315 0.2587% TRP 48.59 0.5796% NGT 53.03 -0.0942% WCN 226.63 -0.0838% MFC 31.51 0.2226% BCE 44.31 -0.2476%

Aequus Pharmaceuticals Inc

Healthcare CA AQS

0.015CAD
-(-%)

Last update at 2024-04-17T13:30:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.030.06
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -1.80959M -1.04536M -3.10610M -2.80374M -3.88243M
Minority interest - - - - -
Net income -1.80959M -1.04536M -3.10610M -2.80374M -3.88243M
Selling general administrative 3.63M 2.96M 3.64M 3.69M 4.06M
Selling and marketing expenses - - - - -
Gross profit 2.69M - - 1.41M 1.14M
Reconciled depreciation 0.13M 0.21M 0.31M 0.19M 0.19M
Ebit -1.60753M -0.77980M -2.44132M -2.80803M -4.00246M
Ebitda -1.22664M -0.31480M -2.37837M -2.62024M -3.72531M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -1.36745M -0.52610M -2.21789M -2.80803M -3.91253M
Other operating expenses - - - - -
Interest expense 0.45M 0.52M 0.42M 0.00000M 0.00000M
Tax provision - - - - 0.00000M
Interest income 0.01M 0.00453M 0.00948M 0.00531M 0.01M
Net interest income -0.44166M -0.51506M -0.40919M 0.00531M 0.01M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - 0.00000M
Total revenue 2.71M 2.59M 1.63M 1.41M 1.14M
Total operating expenses 4.08M 3.12M 3.85M 4.22M 5.05M
Cost of revenue 0.03M - - - 0.00000M
Total other income expense net -0.00048M -0.00420M -0.47902M -0.00102M 0.02M
Discontinued operations - - - - -
Net income from continuing ops -1.80959M -1.04536M -3.10610M -2.80374M -3.88243M
Net income applicable to common shares -1.80959M -1.04536M -3.10610M -2.80374M -3.88243M
Preferred stock and other adjustments - - - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 4.35M 3.13M 1.67M 2.00M 2.67M
Intangible assets - - 0.08M 0.73M 0.90M
Earning assets - - - - -
Other current assets - - - 0.04M 0.08M
Total liab 2.56M 2.56M 2.55M 0.31M 0.37M
Total stockholder equity 1.79M 0.57M -0.87709M 1.68M 2.31M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock 23.99M 21.17M 19.08M 18.93M 17.10M
Capital stock 23.99M 21.17M 19.08M 18.93M -
Retained earnings -26.50948M -24.69989M -23.65453M -20.55010M -17.74636M
Other liab - - - - -
Good will - - - - -
Other assets 0.51M - - - 0.02M
Cash 2.39M 1.72M 0.48M 0.37M 1.16M
Cash and equivalents - - - - -
Total current liabilities 2.46M 0.38M 0.48M 0.31M 0.37M
Current deferred revenue - - - - -
Net debt - 0.26M 1.28M - -
Short term debt - - - - -
Short long term debt 1.93M - - - -
Short long term debt total - - - - -
Other stockholder equity 4.31M 4.10M - - -
Property plant equipment 0.24M 0.37M 0.48M 0.01M 0.00682M
Total current assets 3.59M 2.77M 1.11M 1.24M 1.73M
Long term investments - - - - -
Net tangible assets 1.79M 0.57M -0.96189M 0.93M 1.37M
Short term investments - - - - -
Net receivables 0.94M 0.78M 0.56M 0.73M 0.43M
Long term debt 0.03M 1.98M 1.77M - -
Inventory 0.14M 0.12M 0.00543M 0.01M -
Accounts payable 0.16M 0.16M 0.25M 0.27M 0.34M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.76M 0.96M
Deferred long term asset charges - - - - -
Non current assets total 0.76M 0.37M 0.56M 0.76M 0.96M
Capital lease obligations 0.23M 0.35M 0.45M - -
Long term debt total - - - - -
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments -0.50796M -0.01232M -0.00268M -0.01136M -0.04888M
Change to liabilities 0.14M -0.09541M 0.02M -0.05194M -0.33534M
Total cashflows from investing activities -0.50796M -0.01232M -0.00268M -0.01136M -0.04888M
Net borrowings -0.14751M -0.10383M 1.75M 1.75M 1.75M
Total cash from financing activities 2.40M 2.05M 1.75M 1.79M 4.55M
Change to operating activities 0.07M -0.08519M 0.02M -0.00093M 0.02M
Net income -1.80959M -1.04536M -3.10610M -2.80374M -3.88243M
Change in cash 0.72M 1.23M 0.11M -0.79463M 0.69M
Begin period cash flow 1.72M 0.48M 0.37M 1.16M 0.47M
End period cash flow 2.44M 1.72M 0.48M 0.37M 1.16M
Total cash from operating activities -1.17221M -0.80491M -1.62919M -2.57371M -3.81194M
Issuance of capital stock 2.55M 2.16M 0.00022M 1.79M -
Depreciation 0.13M 0.21M 0.31M 0.17M 0.17M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.01650M -0.11789M 0.00726M -0.01269M -0.01269M
Change to account receivables -0.16156M -0.22322M 0.17M -0.30109M -0.23995M
Sale purchase of stock - - - - 5.17M
Other cashflows from financing activities -0.00575M -0.34458M -0.34458M -0.08455M 0.13M
Change to netincome 0.48M 0.55M 0.95M 0.41M 0.44M
Capital expenditures 0.00412M 0.01M 0.00268M 0.01M 0.05M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.03M -0.52170M 0.22M -0.36665M -0.55549M
Stock based compensation 0.22M 0.30M 0.20M - -
Other non cash items 0.27M 0.25M 0.27M 0.06M 0.07M
Free cash flow -1.17633M -0.81722M -1.63187M -2.58507M -3.86082M

Fundamentals

  • Previous Close 0.01
  • Market Cap3.32M
  • Volume15000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.57413M
  • Revenue TTM0.59M
  • Revenue Per Share TTM0.004
  • Gross Profit TTM 2.69M
  • Diluted EPS TTM-0.02

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AQS
Aequus Pharmaceuticals Inc
- -% 0.01 - - 5.65 24.39 2.90 -2.5557
RX
Biosyent Inc.
-0.1 1.17% 8.45 16.47 16.26 3.21 2.88 2.32 8.03
LOVE
Cannara Biotech Inc
0.01 1.16% 0.87 10.00 - 1.26 0.90 1.98 7.20
DB
Decibel Cannabis Company Inc
-0.005 3.57% 0.14 - 3.38 0.48 1.17 0.87 39.48
LSL
LSL Pharma Group Inc.
- -% 0.41 - - 4.65 4.23 6.13 -14.2493

Reports Covered

Stock Research & News

Profile

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Aequus Pharmaceuticals Inc

200 Granville Street, Vancouver, BC, Canada, V6C 1S4

Key Executives

Name Title Year Born
Mr. Douglas Glen Janzen Chairman, CEO & Pres 1969
Ms. Ann Fehr CGA, CPA CFO & Corp. Sec. 1969
Mr. Stuart Fowler Strategic Commercial Advisor & Independent Director NA
Mr. Grant Larsen Chief Commercial Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).